NAM
HRTX icon

Nexpoint Asset Management’s Heron Therapeutics HRTX Stock Holding History

Nexpoint Asset Management’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-50,000
Closed -$925K – 318
2019
Q3 		$925K Buy
+50,000
New +$920K 0.06% 208

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

Nexpoint Asset Management's HRTX Position: Q1 2026 in Review

Nexpoint Asset Management held its Heron Therapeutics (HRTX) position steady in Q1 2026 at 475,750 shares worth $381K. The position accounts for 0.03% of the portfolio, ranked #79.

Nexpoint Asset Management first reported a position in HRTX in Q3 2019 and has held it in 27 quarters since. The position peaked at $28.1M in Q4 2019. 167 funds tracked by Wall St. Rank hold HRTX as of Q1 2026.

  • Nexpoint Asset Management held 475,750 shares of Heron Therapeutics worth $381K as of Q1 2026.
  • Nexpoint Asset Management left its Heron Therapeutics share count unchanged in Q1 2026.
  • Heron Therapeutics made up 0.03% of Nexpoint Asset Management's portfolio in Q1 2026, its #79 holding.
  • Nexpoint Asset Management first reported a position in Heron Therapeutics in Q3 2019 and has held it in 27 quarters since.
  • Nexpoint Asset Management's Heron Therapeutics position peaked at $28.1M in Q4 2019.
  • 167 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2026.

Based on Nexpoint Asset Management's 13F filing for Q1 2026, filed 15 May 2026.